http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Wei Wenying,Wang Zhen,Yin Yanhua,Han Jinyu,Xu Wen 한국화학공학회 2008 Korean Journal of Chemical Engineering Vol.25 No.3
Composition Group Vector Space (CGVS) method for estimating melting and boiling point Tm, Tb of organic compound has been proposed, and the principle of this method has been elucidated. The models for estimating Tm, Tb have been established and the numerical values of relative parameters have been presented. The average percentage deviations of Tm, Tb estimation are 7.53 and 1.58, respectively, which show that the present method demonstrates significant improvement in applicability to predict the above properties, compared to conventional group methods
ShcD interacts with TrkB via its PTB and SH2 domains and regulates BDNF-induced MAPK activation
( Yuangang You ),( Weiqi Li ),( Yanhua Gong ),( Bin Yin ),( Boqin Qiang ),( Jiangang Yuan ),( Xiaozhong Peng ) 생화학분자생물학회 (구 한국생화학분자생물학회) 2010 BMB Reports Vol.43 No.7
Neurotrophins regulate many aspects of neuronal function through activation of the high affinity Trk receptors. Shc family proteins are implicated in the coupling of RTK to the Ras/mitogen- activated protein kinase signaling cascade. Here we report that the fourth Shc family member, ShcD, associates with TrkB receptor and regulates BDNF-induced MAPK activation. Yeast two-hybrid assay and Co-IP experiments demonstrate ShcD interacts with TrkB in a kinase-activity-dependent manner. Confocal analysis shows ShcD cololizes well with TrkB in transfected 293T cells. Subsequent mapping experiments and mutational analysis indicate that both PTB and SH2 domains are capable of binding to TrkB and PTB domain binds to TrkB NPQY motif. Furthermore, ShcD is involved in BDNF-induced MAPK activation. In summary, we demonstrate that ShcD is a substrate of TrkB and mediates TrkB downstream signaling pathway. [BMB reports 2010; 43(7): 485-490]
Liao Jiwu,Wang Sisi,Zhou Borong,Liang Wei,Ma Ping,Lin Min,Lin Weisen,Li Congrui,Zhang Xiaotao,Li Hongyao,Cui Yin,Hu Jiajia,Qin Yuanyi,Deng Yanhua,Fu Aibing,Zhu Tianhua,Zhang Shanlian,Qu Yunhong,Xing L 대한신경정신의학회 2023 PSYCHIATRY INVESTIGATION Vol.20 No.6
Objective This study’s objective is to assess the efficacy and safety of Pulsed Magnetic Therapy System (PMTS) in improving insomnia disorder.Methods Participants with insomnia disorder were randomly assigned to receive either PMTS or sham treatment for four weeks (n= 153; PMTS: 76, sham: 77). Primary outcomes are the Insomnia Severity Index (ISI) scores at week 0 (baseline), 1, 2, 3, 4 (treatment), and 5 (follow-up). Secondary outcomes are the Pittsburgh Sleep Quality Index at baseline and week 4, and weekly sleep diary-derived values for sleep latency, sleep efficiency, real sleep time, waking after sleep onset, and sleep duration.Results The ISI scores of the PMTS group and the sham group were 7.13±0.50, 11.07±0.51 at week 4, respectively. There was a significant group×time interaction for ISI (F3.214, 485.271=24.25, p<0.001, ηp 2=0.138). Only the PMTS group experienced continuous improvement throughout the study; in contrast, the sham group only experienced a modest improvement after the first week of therapy. At the end of the treatment and one week after it, the response of the PMTS group were 69.7% (95% confidence interval [CI]: 58.6%–79.0%), 75.0% (95% CI: 64.1%–83.4%), respectively, which were higher than the response of the sham group (p<0.001). For each of the secondary outcomes, similar group×time interactions were discovered. The effects of the treatment persisted for at least a week.Conclusion PMTS is safe and effective in improving insomnia disorders.